These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 37858793)

  • 1. Barriers and facilitators to the involvement of general practitioners in the prescription of buprenorphine.
    Gimenez L; Bonis D; Morel M; Palmaro A; Dassieu L; Dupouy J
    J Subst Use Addict Treat; 2024 Jan; 156():209182. PubMed ID: 37858793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Care of Opioid use Disorder: The End of "the French Model"?
    Dupouy J; Maumus-Robert S; Mansiaux Y; Pariente A; Lapeyre-Mestre M
    Eur Addict Res; 2020; 26(6):346-354. PubMed ID: 32155620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribing buprenorphine for opioid use disorder in primary care: A survey of French general practitioners in the Sentinelles network.
    Lépine B; Debin M; Dassieu L; Gimenez L; Palmaro A; Ponté C; Swital M; Lapeyre-Mestre M; Blanchon T; Dupouy J
    J Subst Abuse Treat; 2022 Dec; 143():108891. PubMed ID: 36215914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
    Speight C; Caiola C; Tyndall DE; Scott ES
    J Am Assoc Nurse Pract; 2023 Feb; 35(2):112-121. PubMed ID: 36512806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A qualitative examination of the current management of opioid use disorder and barriers to prescribing buprenorphine in a Canadian emergency department.
    Wiercigroch D; Hoyeck P; Sheikh H; Hulme J
    BMC Emerg Med; 2021 Apr; 21(1):48. PubMed ID: 33858328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers and facilitators for family physicians prescribing opioid agonist therapy in Saskatchewan.
    Nguyen T; Bareham J; Halpape K
    Can Fam Physician; 2024 Apr; 70(4):e52-e60. PubMed ID: 38626996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver.
    Lanham HJ; Papac J; Olmos DI; Heydemann EL; Simonetti N; Schmidt S; Potter JS
    JAMA Netw Open; 2022 May; 5(5):e2212419. PubMed ID: 35552721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methadone and buprenorphine prescribing patterns of Victorian general practitioners: their first 5 years after authorisation.
    Longman C; Lintzeris N; Temple-Smith M; Gilchrist G
    Drug Alcohol Rev; 2011 Jul; 30(4):355-9. PubMed ID: 21355929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. French general practitioners' attitudes toward maintenance drug abuse treatment with buprenorphine.
    Moatti JP; Souville M; Escaffre N; Obadia Y
    Addiction; 1998 Oct; 93(10):1567-75. PubMed ID: 9926562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.
    Calcaterra SL; Lockhart S; Callister C; Hoover K; Binswanger IA
    J Gen Intern Med; 2022 Aug; 37(11):2786-2794. PubMed ID: 34981359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 12. GPs' practices when prescribing buprenorphine in primary care: A survey among the Sentinelles network.
    Lépine B; Debin M; Dassieu L; Gimenez L; Palmaro A; Ponté C; Swital M; Lapeyre-Mestre M; Blanchon T; Dupouy J
    Therapie; 2024 Apr; ():. PubMed ID: 38729825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine prescription by general practitioners in a French region.
    Thirion X; Lapierre V; Micallef J; Ronflé E; Masut A; Pradel V; Coudert C; Mabriez JC; Sanmarco JL
    Drug Alcohol Depend; 2002 Jan; 65(2):197-204. PubMed ID: 11772481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder.
    Varisco T; Shen C; Thornton D
    J Subst Abuse Treat; 2020 Oct; 117():108073. PubMed ID: 32811630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prescription of high dose buprenorphine by general practitioners].
    Feroni I; Paraponaris A; Aubisson S; Bouhnik A; Masut A; Ronfle E; Coudert C; Mabriez JC;
    Rev Epidemiol Sante Publique; 2004 Dec; 52(6):511-22. PubMed ID: 15741914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.
    Leece P; Khorasheh T; Corace K; Strike C; Bayoumi AM; Taha S; Marks E; Pach B; Ahamad K; Grennell E; Holowaty M; Manson H; Straus SE
    BMJ Open; 2019 Dec; 9(12):e032285. PubMed ID: 31843837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM; Schnell MK; Schwandt H; Zhang J
    JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicians' experiences with buprenorphine: A qualitative study of motivations for becoming X waivered and barriers to and facilitators of prescribing the medication for opioid use disorder.
    McCollum CG; Eaton E; Creger T; Lee A; Gagnon K; Li L
    Drug Alcohol Depend; 2023 Mar; 244():109777. PubMed ID: 36680808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers and Facilitators to Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine.
    Hawk KF; D'Onofrio G; Chawarski MC; O'Connor PG; Cowan E; Lyons MS; Richardson L; Rothman RE; Whiteside LK; Owens PH; Martel SH; Coupet E; Pantalon M; Curry L; Fiellin DA; Edelman EJ
    JAMA Netw Open; 2020 May; 3(5):e204561. PubMed ID: 32391893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.